Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

Drug Delivery Systems: Different Types

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...

Modified-Release Drug Delivery Systems: Classification

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gender Differences and Mortality Trends After Transcatheter Aortic Valve Implantation: A 10-Year Analysis From a Single Tertiary Center.

The Journal of invasive cardiology·2021

Same author

Angiography-derived index of microcirculatory resistance (IMR<sub>angio</sub>) as a novel pressure-wire-free tool to assess coronary microvascular dysfunction in acute coronary syndromes and stable coronary artery disease.

The international journal of cardiovascular imaging·2021

Same author

Clinical Conundrum: An Insignificant Impact of Statins on Overall Plaque Volume Regression With Promotion of Calcification?

Circulation. Cardiovascular imaging·2021

Same author

Impact of Endothelial Shear Stress on Absorption Process of Resorbable Magnesium Scaffold: A BIOSOLVE-II Substudy.

Cardiovascular revascularization medicine : including molecular interventions·2021

Same author

Novel device-based therapies to improve outcome in ST-segment elevation myocardial infarction.

European heart journal. Acute cardiovascular care·2021

Same author

Near-Infrared Spectroscopy Intravascular Ultrasound Imaging Evaluation in Patients With Chronic Renal Insufficiency.

JACC. Cardiovascular imaging·2021

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Drug-eluting stents.

Héctor M García-García¹, Sophia Vaina, Keiichi Tsuchida

¹Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.

Archivos De Cardiologia De Mexico

|November 10, 2006

Summary

Drug-eluting stents significantly reduce restenosis after angioplasty by releasing drugs like sirolimus or paclitaxel. Further research is needed for optimal treatment of in-stent restenosis, especially with newer stent designs.

Area of Science:

Interventional Cardiology
Biomaterials Science
Pharmacology

Background:

Stent implantation aims to prevent acute recoil and restenosis post-angioplasty.
Chronic in-stent restenosis is influenced by patient, stent, lesion, and procedural factors.
Drug-eluting stents (DES) deliver drugs locally to inhibit intimal thickening and restenosis.

Purpose of the Study:

To review the development and impact of drug-eluting stents in reducing restenosis.
To discuss the mechanisms of action of drugs used in DES, such as sirolimus and paclitaxel.
To highlight current challenges and future directions in DES technology and restenosis management.

Main Methods:

Review of clinical trials and scientific literature on drug-eluting stents.

More Related Videos

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Related Experiment Videos

Last Updated: Jul 19, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Analysis of stent design, drug delivery mechanisms, and pharmacological agents.

Examination of factors contributing to in-stent restenosis and potential therapeutic strategies.

Main Results:

DES have markedly reduced restenosis rates compared to bare metal stents.
Sirolimus and paclitaxel are effective in inhibiting smooth muscle cell proliferation.
Current DES utilize polymer coatings for drug delivery, with ongoing research into novel materials and designs.

Conclusions:

Drug-eluting stents represent a major advancement in interventional cardiology, significantly improving clinical outcomes.
Optimal treatment for in-stent restenosis following DES implantation requires further investigation.
Future advancements may involve enhanced drug-loading, programmable pharmacokinetic coatings, and novel anti-restenotic compounds.